Low Expression of DDX60 Gene Might Associate with the Radiosensitivity for Patients with Breast Cancer

Dongrun Xin; Jingfang Liu; Jincheng Gu; Yujie Ji; Jiawei Jin; Lu Sun; Qingliang Tai; Jianping Cao; Ye Tian; Hualong Qin; Zaixiang Tang

doi:10.1155/2020/8309492

Low Expression of DDX60 Gene Might Associate with the Radiosensitivity for Patients with Breast Cancer

J Oncol. 2020 Jul 20:2020:8309492. doi: 10.1155/2020/8309492. eCollection 2020.

Authors

Dongrun Xin¹, Jingfang Liu², Jincheng Gu¹, Yujie Ji¹, Jiawei Jin¹, Lu Sun¹, Qingliang Tai¹, Jianping Cao³, Ye Tian⁴, Hualong Qin⁵, Zaixiang Tang^{1

6}

Affiliations

¹ Department of Biostatistics, School of Public Health, Medical College of Soochow University, Suzhou 215123, China.
² Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou 215123, China.
³ State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China.
⁴ Department of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, Suzhou 215123, China.
⁵ Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215123, China.
⁶ Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou 215123, China.

Abstract

DEXD/H box helicase 60 (DDX60) is a new type of DEAD-box RNA helicase, which is induced to express after virus infection. It might involve in antiviral immunity by promoting RIG-I-like receptor-mediated signal transduction. In addition, previous studies had shown that the expression of DDX60 is related to cancer, but there was still a lack of relevant research in breast cancer. In this study, we used the information of patients with breast cancer in the TCGA database for statistical analysis and found that the breast cancer patients with low expression of DDX60 exhibited radiosensitivity. Comparing the radiotherapy groups with the nonradiotherapy groups, for patients with low expression of DDX60, the adjusted hazard ratio (HR) values for radiotherapy were 0.244 (0.064-0.921) and 0.199 (0.062-0.646) in the training and validation datasets, with the p values 0.040 and 0.007, respectively. However, for patients with high expression of DDX60, the adjusted hazard ratio (HR) values were 3.582 (0.627-20.467) and 2.421 (0.460-12.773), with the p values 0.054 and 0.297, respectively. These results suggested that the expression of DDX60 might strongly associate with individualized radiosensitivity in patients with breast cancer.